Chong Kun Dang Holdings Corp. (001630.KS)
KRW 50100.0
(-0.6%)
KRW 50100.0
(-0.6%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 33.14 Billion KRW | 200.75% |
| 2022 | -16.87 Billion KRW | -149.05% |
| 2021 | 34.41 Billion KRW | -74.19% |
| 2020 | 133.32 Billion KRW | 54.74% |
| 2019 | 86.15 Billion KRW | 60.4% |
| 2018 | 53.71 Billion KRW | 23.5% |
| 2017 | 43.49 Billion KRW | 88.7% |
| 2016 | 23.05 Billion KRW | -18.21% |
| 2015 | 28.18 Billion KRW | -8.29% |
| 2014 | 30.72 Billion KRW | -62.72% |
| 2013 | 82.44 Billion KRW | 4.76% |
| 2012 | 78.69 Billion KRW | -9.92% |
| 2011 | 87.35 Billion KRW | 15.71% |
| 2010 | 75.49 Billion KRW | 48.73% |
| 2009 | 50.75 Billion KRW | 3.64% |
| 2008 | 48.97 Billion KRW | 50.35% |
| 2007 | 32.57 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 12.52 Billion KRW | 433.39% |
| 2024 Q2 | 8.56 Billion KRW | -3.68% |
| 2023 Q3 | 3.6 Billion KRW | 118.61% |
| 2023 Q2 | 1.64 Billion KRW | -91.78% |
| 2023 Q1 | 20.02 Billion KRW | 401.99% |
| 2023 Q4 | 2.34 Billion KRW | -34.78% |
| 2023 FY | 17 Billion KRW | 200.75% |
| 2022 Q4 | -6.63 Billion KRW | 8.37% |
| 2022 Q1 | 4.84 Billion KRW | 876.62% |
| 2022 FY | -16.87 Billion KRW | -149.05% |
| 2022 Q2 | -7.85 Billion KRW | -262.06% |
| 2022 Q3 | -7.23 Billion KRW | 7.85% |
| 2021 Q2 | 6.36 Billion KRW | -70.54% |
| 2021 FY | 34.41 Billion KRW | -74.19% |
| 2021 Q4 | -624.12 Million KRW | -108.85% |
| 2021 Q1 | 21.61 Billion KRW | 173.09% |
| 2021 Q3 | 7.05 Billion KRW | 10.77% |
| 2020 Q4 | 7.91 Billion KRW | -64.85% |
| 2020 Q2 | 26.46 Billion KRW | -18.25% |
| 2020 Q1 | 32.36 Billion KRW | 162.29% |
| 2020 FY | 133.32 Billion KRW | 54.74% |
| 2020 Q3 | 22.51 Billion KRW | -14.91% |
| 2019 Q4 | 12.34 Billion KRW | -52.84% |
| 2019 FY | 86.15 Billion KRW | 60.4% |
| 2019 Q1 | 20.29 Billion KRW | 60.8% |
| 2019 Q2 | 27.35 Billion KRW | 34.8% |
| 2019 Q3 | 26.16 Billion KRW | -4.35% |
| 2018 Q1 | 13.89 Billion KRW | 50.95% |
| 2018 Q2 | 12.68 Billion KRW | -8.69% |
| 2018 Q4 | 12.62 Billion KRW | -13.02% |
| 2018 Q3 | 14.51 Billion KRW | 14.37% |
| 2018 FY | 53.71 Billion KRW | 23.5% |
| 2017 Q4 | 9.2 Billion KRW | -35.95% |
| 2017 Q2 | 10.86 Billion KRW | 19.97% |
| 2017 Q1 | 9.05 Billion KRW | 82.99% |
| 2017 FY | 43.49 Billion KRW | 88.7% |
| 2017 Q3 | 14.37 Billion KRW | 32.3% |
| 2016 Q3 | 6.57 Billion KRW | 45.37% |
| 2016 Q1 | 7.01 Billion KRW | 9.86% |
| 2016 Q4 | 4.94 Billion KRW | -24.77% |
| 2016 FY | 23.05 Billion KRW | -18.21% |
| 2016 Q2 | 4.52 Billion KRW | -35.49% |
| 2015 Q1 | 6.89 Billion KRW | 34.53% |
| 2015 Q4 | 6.38 Billion KRW | -11.32% |
| 2015 Q3 | 7.19 Billion KRW | -6.53% |
| 2015 Q2 | 7.7 Billion KRW | 11.7% |
| 2015 FY | 28.18 Billion KRW | -8.29% |
| 2014 Q1 | 10.75 Billion KRW | -12.17% |
| 2014 Q4 | 5.12 Billion KRW | -12.24% |
| 2014 FY | 30.72 Billion KRW | -62.72% |
| 2014 Q3 | 5.84 Billion KRW | -35.14% |
| 2014 Q2 | 9 Billion KRW | -16.31% |
| 2013 Q2 | 25.62 Billion KRW | 27.21% |
| 2013 Q3 | 24.13 Billion KRW | -5.82% |
| 2013 Q4 | 12.25 Billion KRW | -49.24% |
| 2013 FY | 82.44 Billion KRW | 4.76% |
| 2013 Q1 | 20.14 Billion KRW | 18.97% |
| 2012 Q1 | 10.3 Billion KRW | 0.0% |
| 2012 Q2 | 22.73 Billion KRW | 120.67% |
| 2012 Q3 | 25.03 Billion KRW | 10.15% |
| 2012 Q4 | 16.93 Billion KRW | -32.38% |
| 2012 FY | 78.69 Billion KRW | -9.92% |
| 2011 Q2 | 21 Billion KRW | 21.72% |
| 2011 FY | 87.35 Billion KRW | 15.71% |
| 2011 Q1 | 17.25 Billion KRW | 0.0% |
| 2011 Q3 | 21.64 Billion KRW | 3.06% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | 16.36 Billion KRW | 2.94% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 FY | 75.49 Billion KRW | 48.73% |
| 2010 Q2 | 15.9 Billion KRW | 33.44% |
| 2010 Q1 | 11.91 Billion KRW | 0.0% |
| 2009 Q3 | 12.38 Billion KRW | 27.08% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q2 | 9.74 Billion KRW | 8.43% |
| 2009 Q1 | 8.98 Billion KRW | 0.0% |
| 2009 FY | 50.75 Billion KRW | 3.64% |
| 2008 Q1 | 10.01 Billion KRW | 0.0% |
| 2008 Q3 | 10.19 Billion KRW | -8.69% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 11.16 Billion KRW | 11.51% |
| 2008 FY | 48.97 Billion KRW | 50.35% |
| 2007 Q1 | 9.11 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 Q3 | 7.41 Billion KRW | -24.18% |
| 2007 Q2 | 9.77 Billion KRW | 7.2% |
| 2007 FY | 32.57 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -8992.864% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 56.886% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 141.662% |
| HANDOK Inc. | 12.57 Billion KRW | -163.513% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 1766.389% |
| Yuhan Corporation | 74.56 Billion KRW | 55.545% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -196.524% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 283.715% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 85.261% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -984.627% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -130.982% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -5457.798% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -3339.308% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -22.623% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -8992.864% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 527.368% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -721.763% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 147.386% |
| JW Holdings Corporation | 143.66 Billion KRW | 76.928% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 162.052% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 86.558% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 66.954% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 169.941% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -378.522% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -412.235% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -279.629% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -8992.864% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 32.031% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 75.154% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 66.954% |
| Yuhan Corporation | 74.56 Billion KRW | 55.545% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -58.444% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -963.287% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 22.905% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 66.954% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -61.816% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 39.678% |
| CKD Bio Corp. | -20.15 Billion KRW | 264.48% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | -2.836% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -31.005% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | -1.912% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 169.941% |
| Boryung Corporation | 68.26 Billion KRW | 51.445% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 188.399% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -130.982% |
| JW Lifescience Corporation | 32.09 Billion KRW | -3.289% |